This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-APB: Difference between revisions
>Kenan m Text replacement - "The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects." to "{{Preamble/SubjectiveEffects}}" |
>Unity No edit summary |
||
| Line 5: | Line 5: | ||
| ''[[ 5-APB/Summary|Summary sheet: 5-APB]]'' | | ''[[ 5-APB/Summary|Summary sheet: 5-APB]]'' | ||
|} | |} | ||
'''5- | '''1-Benzofuran-5-ylpropan-2-amine''' (abbreviated '''5-APB''' ) is a [[Psychoactive class::entactogen]]ic drug of the [[chemical class::phenethylamine]] and [[chemical class::benzofuran]] classes. | ||
This compound is known for its [[stimulating]] and [[euphoria|euphoric]] effects which has resulted in its rise in popularity as a product which is easily accessible through the use of certain online [[research chemical]] vendors. It has been sold as a [[designer drug]] since 2010.<ref>EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | http://www.emcdda.europa.eu/publications/implementation-reports/2010</ref> | This compound is known for its [[stimulating]] and [[euphoria|euphoric]] effects which has resulted in its rise in popularity as a product which is easily accessible through the use of certain online [[research chemical]] vendors. It has been sold as a [[designer drug]] since 2010.<ref>EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | http://www.emcdda.europa.eu/publications/implementation-reports/2010</ref> | ||
| Line 53: | Line 53: | ||
*'''[[Effect::Thought deceleration]]''' | *'''[[Effect::Thought deceleration]]''' | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' | ||
===Experience reports=== | ===Experience reports=== | ||
Anecdotal reports which describe the effects of this compound within our [[experience index]] include: | |||
{{#ask: [[Category:5-APB]][[Category:Experience]]|format=ul|Columns=1}} | |||
Additional experience reports can be found here: | |||
* [https://www.erowid.org/experiences/subs/exp_5APB.shtml Erowid Experience Vaults: 5-APB] | * [https://www.erowid.org/experiences/subs/exp_5APB.shtml Erowid Experience Vaults: 5-APB] | ||
| Line 82: | Line 86: | ||
==Legal issues== | ==Legal issues== | ||
{{legalStub}} | {{legalStub}} | ||
*''' | *'''United Kingdom:''' 5-APB is a Class B drug. | ||
*''' | *'''United States:''' 5-APB could be considered an analogue of [[MDA]] and therefore would be covered under the Federal Analogue Act if intended for human consumption. | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Designer drug]] | |||
*[[Psychedelics]] | *[[Psychedelics]] | ||
*[[Entactogens]] | *[[Entactogens]] | ||
*[[Stimulants]] | *[[Stimulants]] | ||
*[[Phenethylamines]] | *[[Phenethylamines]] | ||
*[[ | *[[6-APB]] | ||
*[[MDA]] | *[[MDA]] | ||
*[[MDAI]] | *[[MDAI]] | ||
| Line 99: | Line 104: | ||
*[http://drugs.tripsit.me/5-apb 5-APB (Tripsit)] | *[http://drugs.tripsit.me/5-apb 5-APB (Tripsit)] | ||
*[https://en.wikipedia.org/wiki/5-APB 5-APB (Wikipedia)] | *[https://en.wikipedia.org/wiki/5-APB 5-APB (Wikipedia)] | ||
*[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-APB-Thread The Big and Dandy 5-APB Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-APB-Thread The Big and Dandy 5-APB Thread (Bluelight)] | ||
| Line 106: | Line 110: | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Research chemical]] | |||
[[Category:Amphetamine]] | [[Category:Amphetamine]] | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||
[[Category:Benzofuran]] | [[Category:Benzofuran]] | ||